Vitaxin Applied Molecular Evolution

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 199-203

  Mikecz, K ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; INTEGRIN RECEPTOR; MONOCLONAL ANTIBODY LM 609; VITRONECTIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; APOPTOSIS; CANCER INVASION; CELL ADHESION; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; HEADACHE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; JOINT DEGENERATION; LEIOMYOSARCOMA; METASTASIS; MYALGIA; NAUSEA; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOMA; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033760662     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Peptide and antibody used to shrink tumors
2. Integrin αvβ3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels
3. Extracellular matrix stimulation of guine pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor
4. Ixsys Incorporated (company brochure)
5. Ixsys licenses novelanti-angiogenesis/cancer agent from Scripps research institute
6. Therapeutic implications of angiogenesis inhibitors and stimulators Dec 11-12 1995
7. Integrin αvβ3: Preclinical and clinical development of a humanized monoclonal antibody antagonist
8. Ixsys initiates phase I clinical safety trial with Vitaxin for treating patients with incurable malignancies
9. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin
10. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, firbrinogen, and von Wilebrand factor
11. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachement to fibrinogen and von Willebrand factor
12. Molecular determinants of cancer metastasis, 50th annual symposium fundamental cancer research, Houston, TX, USA
13. American society of clinical oncology 34th annual meeting (part IV), Los Angeles, California, USA
14. Phase I study of Vitaxin, an anti-angiogenic humanized monoclonal antibody to vascular integrin αvβ3
15. ImmmunoStrategies 98, recombinant antibodies for pioneering therapeutics, Arlington, VA, USA
16. Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb
17. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
18. Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas
19. Ixsys: Angiogenesis research on vitaxin results reported 05/16/98
20. Ixsys In initiates phase II cancer trial
21. MedImmune and Ixsys enter four product antibody alliance - Lead product in phase II for cancer treatment by inhibition of angiogenesis
22. Antibodies and hybridomas - Sevent international conference (part II), Edinburgh, UK
23. Angiogenesis: Therapeutic applications - Second annual meeting, Washington DC, USA
24. Angiogenesis and arthritis
25. Experimental biology 2000, recent progress in cancer biology and therapy, Sand Diego, CA, USA
26. A pilot study of an angiogenesis inhibitor Vitaxin in patients with advanced leiomyosarcomas (leios)
27. Summary of the 36th annual meeting of the American society of clinical oncology, New Oleans, LA, USA
28. Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
29. Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist
30. Analysis of the histologic variation of synovitis in rheumatoid arthritis
31. Angiogenesis in rheumatoid arthritis: Implications for future therapeutic strategies